Safety and efficacy of intensive vs. guideline antiplatelet therapy in high‐risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388)
DiscussionThe trial has recruited more than 50% of its target sample size (latest number: 2399) and is running in 104 sites in 4 countries. One‐third of patients presented with a transient ischemic attack.
Source: International Journal of Stroke - Category: Neurology Tags: Protocol Source Type: research
More News: Aspirin | Bleeding | Cardiology | Clopidogrel | Disability | Heart | Internet | Ischemic Stroke | Neurology | Plavix | Stroke | Study | Websites